Eisai Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

E7080-G000-303

Study Overview

E7080
lenvatinib
NCT01321554, EU CTR 2010-023783-41
Mar 2011 - Nov 2013
Differentiated Thyroid Cancer
Progression-free survival (PFS)

  • Males and females (age 18 and over)

  • Active, not recruiting

  • Phase 3

  • Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czech Republic, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Poland, Portugal, Romania, Russian Federation, Spain, Sweden, Thailand, United Kingdom, United States See more

Results

CSR Synopsis

Download PDF

Lay Summary

Download PDF
Publication reference citation

Schlumberger SI et al. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. N Engl J Med 2015; 372 (7): 621-630.
DOI: 10.1056/NEJMoa1406470

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR